Filing Details
- Accession Number:
- 0001203311-23-000087
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-08-29 18:22:59
- Reporting Period:
- 2023-08-28
- Accepted Time:
- 2023-08-29 18:22:59
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1060736 | Seagen Inc. | SGEN | Biological Products, (No Disgnostic Substances) (2836) | 911874389 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1206199 | G Daniel Welch | 21823 30Th Drive Se Bothell WA 98021 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-08-28 | 1,812 | $135.63 | 10,109 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-08-28 | 1,503 | $209.16 | 8,606 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-08-28 | 1,812 | $209.01 | 6,794 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-08-28 | 1,610 | $209.08 | 10,725 | No | 4 | S | Indirect | by Trust |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Indirect | by Trust |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2023-08-28 | 1,812 | $0.00 | 1,812 | $135.63 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2023-05-13 | 2032-05-13 | No | 4 | M | Direct |
Footnotes
- Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
- Sales reported in this Form 4 were effected pursuant to written plans, entered into on September 7, 2022, that are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
- Reflects sales of common stock executed in multiple transactions at prices ranging from $209.06 to $209.25. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- Reflects sales of common stock executed in multiple transactions at prices ranging from $208.92 to $209.21. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- Reflects sales of common stock executed in multiple transactions at prices ranging from $208.92 to $209.25. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- Options vested in full on 5/13/23.
Billionaire Hedge Funds
